| herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells E Lastraioli, L Guasti, O Crociani, S Polvani, G Hofmann, H Witchel, ... Cancer research 64 (2), 606-611, 2004 | 317 | 2004 |
| Psychotropic drugs, cardiac arrhythmia, and sudden death HJ Witchel, JC Hancox, DJ Nutt Journal of clinical psychopharmacology 23 (1), 58-77, 2003 | 304 | 2003 |
| Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current HJ Witchel, JC Hancox Clinical and Experimental Pharmacology and Physiology 27 (10), 753-766, 2000 | 239 | 2000 |
| Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 JT Milnes, O Crociani, A Arcangeli, JC Hancox, HJ Witchel British journal of pharmacology 139 (5), 887-898, 2003 | 212 | 2003 |
| Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine AA Paul, HJ Witchel, JC Hancox British journal of pharmacology 136 (5), 717-729, 2002 | 186 | 2002 |
| Acquired QT interval prolongation and HERG: implications for drug discovery and development K Finlayson, HJ Witchel, J McCulloch, J Sharkey European journal of pharmacology 500 (1-3), 129-142, 2004 | 174 | 2004 |
| Time course and voltage dependence of expressed HERG current compared with native” rapid” delayed rectifier K current during the cardiac ventricular action potential JC Hancox, AJ Levi, HJ Witchel Pflügers Archiv 436, 843-853, 1998 | 158 | 1998 |
| Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline AG Teschemacher, EP Seward, JC Hancox, HJ Witchel British journal of pharmacology 128 (2), 479-485, 1999 | 155 | 1999 |
| Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents HJ Witchel, VK Pabbathi, G Hofmann, AA Paul, JC Hancox FEBS letters 512 (1-3), 59-66, 2002 | 153 | 2002 |
| The N588K-HERG K+ channel mutation in the ‘short QT syndrome’: Mechanism of gain-in-function determined at 37°C MJ McPate, RS Duncan, JT Milnes, HJ Witchel, JC Hancox Biochemical and biophysical research communications 334 (2), 441-449, 2005 | 145 | 2005 |
| Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes HJ Witchel, JT Milnes, JS Mitcheson, JC Hancox Journal of pharmacological and toxicological methods 48 (2), 65-80, 2002 | 145 | 2002 |
| Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin AJ Alexandrou, RS Duncan, A Sullivan, JC Hancox, DJ Leishman, ... British journal of pharmacology 147 (8), 905-916, 2006 | 138 | 2006 |
| The low-potency, voltage-dependent HERG blocker propafenone—molecular determinants and drug trapping HJ Witchel, CE Dempsey, RB Sessions, M Perry, JT Milnes, JC Hancox, ... Molecular pharmacology 66 (5), 1201-1212, 2004 | 127 | 2004 |
| Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder SV Argyropoulos, SD Hood, M Adrover, CJ Bell, AS Rich, JR Nash, ... Biological psychiatry 56 (7), 503-509, 2004 | 122 | 2004 |
| Design tools for interdisciplinary translation of material experiences S Wilkes, S Wongsriruksa, P Howes, R Gamester, H Witchel, M Conreen, ... Materials & Design 90, 1228-1237, 2016 | 113 | 2016 |
| Pharmacology of the short QT syndrome N588K‐hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs MJ McPate, RS Duncan, JC Hancox, HJ Witchel British journal of pharmacology 155 (6), 957-966, 2008 | 113 | 2008 |
| Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 C: Cisapride versus dofetilide JT Milnes, HJ Witchel, JL Leaney, DJ Leishman, JC Hancox Journal of pharmacological and toxicological methods 61 (2), 178-191, 2010 | 107 | 2010 |
| Drug‐induced hERG block and long QT syndrome HJ Witchel Cardiovascular therapeutics 29 (4), 251-259, 2011 | 105 | 2011 |
| High affinity HERG K+ channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656 JM Ridley, JT Milnes, HJ Witchel, JC Hancox Biochemical and biophysical research communications 325 (3), 883-891, 2004 | 102 | 2004 |
| Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome MJ McPate, RS Duncan, HJ Witchel, JC Hancox Journal of molecular and cellular cardiology 41 (3), 563-566, 2006 | 95 | 2006 |
Jules HancoxProfessor of Cardiac Electrophysiology, University of BristolVahvistettu sähköpostiosoite verkkotunnuksessa bristol.ac.uk
